Core Points - The company announced that the third extraordinary general meeting of shareholders in 2025 will be held on December 2 at 14:45 to review the proposal for the sale of equity in an associated company [1] - The company plans to sign an agreement with Xu Haijian and others, who will collectively acquire 15% equity in Suzhou Kamenhas Laser Technology Co., Ltd. for 75 million yuan, corresponding to a registered capital of 4.1667 million yuan [1] - This transaction does not constitute a related party transaction or a major asset restructuring, and if implemented, it will enhance asset operational efficiency [1] - The meeting will adopt a combination of on-site and online voting for decision-making [1]

Core Viewpoint - The company is actively pursuing strategic expansion in overseas markets while continuing to strengthen its domestic market presence [1] Group 1: Overseas Market Strategy - The company is exploring markets in Hong Kong, Macau, and Taiwan, but has not yet entered the EU market [1] - Future plans include ongoing efforts to expand internationally, leveraging opportunities presented by the deepening global digital economy [1] Group 2: Domestic Market Focus - The company emphasizes the importance of solidifying its position in the domestic market as a foundation for future international growth [1]

Core Viewpoint - The company, Jin Chengzi, announced a share transfer agreement involving the sale of a 15% stake in Suzhou Kamenhas Laser Technology Co., Ltd. for a total consideration of RMB 75 million [2] Group 1: Transaction Details - The share transfer agreement was signed with several parties, including Xu Haijian, Xu Haifeng, Guo Yonghua, and others, who will collectively acquire the stake [2] - The registered capital of Kamenhas is RMB 416.67 million, and the transaction represents a 15% ownership interest in the company [2] - The transaction has been approved by the company's board of directors and is pending approval from the shareholders' meeting [2]

Group 1 - China Pacific Insurance's subsidiary, China Pacific Life, reported a cumulative premium income of 241.32 billion yuan for the first ten months, a year-on-year increase of 9.9% [1] - China Pacific Property Insurance, another subsidiary, achieved a cumulative premium income of 173.57 billion yuan, with a year-on-year growth of 0.4% [1] - Nocera Biopharma reported a net loss of 64.41 million yuan for the first three quarters, despite a revenue increase of 59.85% to 1.115 billion yuan [1] Group 2 - Founder Securities received approval from the China Securities Regulatory Commission to issue short-term corporate bonds not exceeding 5 billion yuan [1] - Haicheng Bonda's director plans to reduce his stake by up to 0.97%, equating to 198,400 shares [1] - Yuyuan Group intends to repurchase shares worth between 200 million and 300 million yuan, with a maximum price of 8.60 yuan per share [1] Group 3 - Huaren Shuanghe's subsidiary passed the GMP compliance inspection for a specific diabetes medication [4] - Lichong Group received project notifications from three international automotive manufacturers, with expected sales amounting to approximately 1.135 billion yuan [6] - Deyang Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy [7] Group 4 - Longxin General announced the transfer of its entire stake in a subsidiary for 105.6 million yuan, and also plans to divest another stake for 1 yuan due to poor performance [16] - Kangda New Materials decided to terminate the acquisition of a semiconductor company due to unsatisfactory due diligence progress [17] - Lu'an Environmental reported a 3.28% year-on-year increase in coal sales for October, totaling 3.78 million tons [18] Group 5 - Shanghai Port Group plans to invest 2 billion yuan to establish a new holding company with several state-owned enterprises [20] - Borui Pharmaceutical's new drug for obesity treatment has received clinical trial approval [23] - Silver Dragon Co. has completed the registration of a new energy industry fund focusing on high-growth potential projects [24] Group 6 - Hengrui Medicine received approval for a clinical trial of a prostate cancer drug [11] - Baiji Shenzhou reported a net profit of 1.139 billion yuan for the first three quarters, marking a turnaround from losses [36] - Huasheng Pharmaceutical's special medical food product has received registration certification [60]

证券代码：688291 证券简称：金橙子 公告编号：2025-052 北京金橙子科技股份有限公司 关于出售参股公司股权的公告 本次交易已经公司 2025 年 11 月 13 日召开的第四届董事会第十七次会议审议 通过，根据《上海证券交易所科创板股票上市规则》（以下简称"《上市规则》"） 及《北京金橙子科技股份有限公司章程》（以下简称"《公司章程》"）等有关 1 本次交易不构成关联交易 本次交易不构成重大资产重组 交易实施尚需履行的审批及其他相关程序： 规定，本次交易尚需提交公司股东会审议。 其他需要提醒投资者重点关注的风险事项： （一）本次交易股权转让价款支付周期较长，存在不能按协议约定支付股权 转让价款的履约风险。 （二）本次交易实施过程中可能存在市场、经济与政策法律变化等不可预见 因素的影响，且需完成工商变更登记或备案，故本次交易最终能否实施并完成存 在不确定性。 （三）本次交易因尚需履行股东会审议、相关方需完成协议签署、按约定支 付股权转让价款并完成工商变更登记或备案等手续，具体完成时间存在不确定性。 公司将持续关注交易进展，并严格按照相关法律法规及监管要求，及时履行信息 披露义务，确保交易的合规性与透 ...

重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2025年第三次临时股东会 （二） 股东会召集人：董事会 证券代码：688291 证券简称：金橙子 公告编号：2025-053 北京金橙子科技股份有限公司 关于召开2025年第三次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （三） 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 12 月 2 日 14 点 45 分 召开地点：北京市丰台区科兴路 7 号 3 层 308 公司会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 12 月 2 日 至2025 年 12 月 2 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过 股东会召开日期：202 ...

Core Viewpoint - The company Jin Chengzi (688291.SH) plans to transfer a 15% equity stake in Suzhou Kamenhas Laser Technology Co., Ltd. for a total consideration of RMB 75 million, which is aimed at improving asset operation efficiency and supporting business expansion [1] Group 1 - The equity transfer involves multiple parties, including Xu Haijian, Xu Haifeng, Guo Yonghua, Zhou Zhikai, and several limited partnerships [1] - The registered capital of Kamenhas is RMB 416.67 million, and the company will retain a 15% stake post-transaction [1] - The transaction is based on a comprehensive consideration of the company's development situation and is expected to enhance sustainable development capabilities [1]

Core Viewpoint - The company plans to sell a 15% stake in Suzhou Kamenhas Laser Technology Co., Ltd. for 75 million yuan, which is aimed at improving asset operation efficiency and providing funding support for business expansion [1] Group 1 - The company will enter into a share transfer agreement with Xu Haijian and Xu Haifeng [1] - The sale of the stake is based on a comprehensive consideration of the company's development situation [1] - If the transaction is successfully implemented, it will benefit the company's asset operation efficiency [1]

Core Viewpoint - The company, Jin Chengzi (688291.SH), plans to sell a 15% stake in its subsidiary, Kamenhas, for RMB 75 million, aiming to enhance operational efficiency and support sustainable development [1] Group 1 - The company will enter into a share transfer agreement with other shareholders of Kamenhas [1] - The stake being sold represents a registered capital of RMB 416.67 million [1] - The transaction is based on a comprehensive consideration of the company's development situation [1] Group 2 - Successful implementation of the transaction is expected to improve asset operation efficiency and reduce management costs [1] - The sale will provide financial support for business expansion and enhance the company's sustainability [1]

审计报告 苏州卡门哈斯激光技术有限责任公司 容诚审字[2025]215Z0758号 容诚会计师事务所(特殊普通合伙) 中国·北京 目 录 | 序号 | 内 | 容 | 页码 | | --- | --- | --- | --- | | 1 | 审计报告 | | 1 - 4 | | 2 | 资产负债表 | | 1 | | 3 | 利润表 | | 2 | | 4 | 现金流量表 | | 3 | | 5 | 所有者权益变动表 | | 4 | | 6 | 财务报表附注 | | 5 - 52 | 容诚会计师事务所（特殊普通合伙） 总所：北京市西城区阜成门外大街 22 号 1 幢 10 层 1001-1 至 1001-26 (100037) TEL:010-6600 1391 FAX:010-6600 1392 E-mail:bj@rsmchina.com.cn https://www.rsm.global/china/ 审 计 报 告 容诚审字[2025]215Z0758号 苏州卡门哈斯激光技术有限责任公司全体股东： 一、审计意见 我们审计了苏州卡门哈斯激光技术有限责任公司（以下简称卡门哈斯）财务 报表，包括 2025 ...